Kuros Biosciences AG
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG000BX17Y0
KURN
Kuros Biosciences AG
GICS: -
·
Sector: -
·
Sub-Sector: -
NAME
Kuros Biosciences AG
ISIN
CH0325814116
TICKER
KURN
MIC
XSWX
REUTERS
KURN.S
BLOOMBERG
KURN SW
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Tue, 19.11.2024
Kuros Biosciences AG
/ Key word(s): Miscellaneous/Personnel
Kuros Biosciences Expands into Extremities Markets 19.11.2024 / 07:00 CET/CEST
Commercial Highlights
Appointment of Jantzen Cole as Vice President of Market Development, Extremities, to drive the Company’s acceleration beyond the spine market
Strategic expansion op...
Thu, 10.10.2024
Financial Highlights
Direct MagnetOsTM sales rose by 149% to CHF 50.6 million in the first nine months of 2024, from CHF 20.4 million in the same period in 2023
Total Kuros Medical Devices segment sales accelerated to CHF 51.1 million in Q3 2024 from CHF 21.3 million in Q3 2023 year to date
Kuros Medical Devices segment EBITDA increased to CHF ...
Thu, 08.08.2024
Financial Highlights
Direct MagnetOs™ sales increased by 159% to CHF 31.6 million from CHF 12.2 million in H1 2023; this corresponds to a sequential increase of 62% or CHF 12.1 million over H2 2023
Total Kuros Medical Devices segment sales increased 148% to CHF 31.8 million from CHF 12.9 million
Kuros Medical Devices segment EBITDA increased 287...
Tue, 25.06.2024
Kuros Biosciences AG
/ Key word(s): Study results/Scientific publication
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft 25.06.2024 / 07:00 CET/CEST
Schlieren (Zurich), Switzerland, June 25, 2024 – Kuros Biosciences, a leader in next ...
Wed, 24.04.2024
Financial Highlights
Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023; this corresponds to a sequential increase of 21.9% or CHF 2.5 million over Q4 2023
Total Kuros Medical Devices segment sales accelerated to CHF 13.9 million in Q1 2024 from CHF 5.6 million in Q1 2023
Kuros Medical Devices segm...
Wed, 17.04.2024
Kuros Biosciences AG
/ Key word(s): AGMEGM
Annual General Meeting of Kuros Biosciences approves all resolutions 17.04.2024 / 14:05 CET/CEST
Schlieren (Zurich), Switzerland, April 17, 2024 – Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today.
The Annual Gen...
Wed, 13.03.2024
Financial highlights
Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million in 2022. Total medical device sales accelerated by 153% from CHF 13.3 million in 2022 to CHF 33.6 million in 2023
The Medical Devices segment achieved a positive EBITDA of CHF 6.8 million driven by MagnetOs
Cash and cash equivalen...
Fri, 08.03.2024
Kuros Biosciences AG
/ Key word(s): Annual Results
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update 08.03.2024 / 07:00 CET/CEST
- Company to host conference call and webcast on March 13, 2024, at 3pm CET/10am US EST
Schlieren (Zurich), Switzerland, March 8, 2024 – Kuros Bioscienc...
Thu, 01.02.2024
Kuros Biosciences AG
/ Key word(s): Conference
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference 01.02.2024 / 07:00 CET/CEST
Schlieren (Zurich), Switzerland, February 1, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it will present...
Wed, 31.01.2024
Kuros Biosciences AG
/ Key word(s): Regulatory Admission/Market Launch
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand 31.01.2024 / 07:00 CET/CEST
MagnetOs™ Granules becomes the third product in the MagnetOs...
Information on product placements
